On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022. In connection with Dr. Madan's resignation, it is expected that the Company will enter into a consulting agreement for a period of six months with Dr. Madan pursuant to which he will assist with the transition of his duties to others within the Company and to ensure the continuity of its programs while it searches for his replacement.